Drug Type Small molecule drug |
Synonyms PORT 6, TT-10 |
Target |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists), TEAD1 inhibitors(TEA domain transcription factor 1 inhibitors), YAP1 inhibitors(65 kDa Yes-associated protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Start Date23 Jun 2023 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Phase 2 | US | 23 Jun 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 23 Jun 2023 | |
Renal Cell Carcinoma | Phase 2 | US | 23 Jun 2023 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | US | 23 Jun 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |